Melanie Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Melanie Schmidt has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Johannes Dietl
5 shared publicationsUlrike Kammerer
5 shared publicationsHans-Ullrich Voelker
4 shared publicationsMichaela Kapp
3 shared publicationsAndré Michael Schmidt
2 shared publicationsMathias Krockenberger
2 shared publications
Latest Publications
- 1 May 2010
- Vol. 30 (5) , 1689-94
The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer.
Cancer cell growth has been described to depend on glucose utilization. Activation of Akt and up-regulation of pyruvate kinase M2 (M2-PK) are attributes of tumour glycolysis. In order to evaluate the prognostic relevance of glycolytic markers in breast cancer, the expression of pAkt and M2PK was analysed in 160 tissue samples. The staining results were compared with clinicopathological characteristics and survival data. Overexpression of pAkt was detected in 58% and of M2PK in 70% of breast cancer samples. Increased pAkt-expression was accompanied with shorter survival time. In contrast, M2PK expression was significantly higher in patients surviving breast cancer for more than 13 years. Strong M2PK expression seems to be a favourable prognostic factor and its role in breast cancer progression should be further explored. Our data confirm previous observations of pAkt as a negative prognostic marker.
- 1 May 2010
- Vol. 30 (5) , 1689-94
The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer.
Cancer cell growth has been described to depend on glucose utilization. Activation of Akt and up-regulation of pyruvate kinase M2 (M2-PK) are attributes of tumour glycolysis. In order to evaluate the prognostic relevance of glycolytic markers in breast cancer, the expression of pAkt and M2PK was analysed in 160 tissue samples. The staining results were compared with clinicopathological characteristics and survival data. Overexpression of pAkt was detected in 58% and of M2PK in 70% of breast cancer samples. Increased pAkt-expression was accompanied with shorter survival time. In contrast, M2PK expression was significantly higher in patients surviving breast cancer for more than 13 years. Strong M2PK expression seems to be a favourable prognostic factor and its role in breast cancer progression should be further explored. Our data confirm previous observations of pAkt as a negative prognostic marker.
- 5 August 2009
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (2) , 219-225
Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK
Metabolic dependence on glucose utilisation has been described for different tumours characterised by activation of Akt, upregulation of GLUT1, M2PK and TKTL1. To date, however, little is known about glucose metabolism in breast cancer tissue. We analysed 55 breast cancer specimens, 26 adjacent ductal carcinomas in situ (DCIS) and 23 adjacent normal breast tissues for expression of glycolytic markers by immunohistochemistry. We found expression of pAkt in 49%, GLUT1 in 25%, M2PK in 68% and TKTL1 in 31% of the tumours investigated. Expression of pAkt and Her2neu are positively correlated with borderline significance (P = 0.055). Expression of pAkt, GLUT1 and TKTL1 were higher in breast cancer and DCIS than in normal tissue. Surprisingly, M2PK expression was highest in normal breast tissue. We found a glycolytic phenotype in a high percentage of breast cancer samples. Inhibition of glycolysis might evolve as a future option for breast cancer therapy.
- 5 August 2009
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (2) , 219-225
Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK
Metabolic dependence on glucose utilisation has been described for different tumours characterised by activation of Akt, upregulation of GLUT1, M2PK and TKTL1. To date, however, little is known about glucose metabolism in breast cancer tissue. We analysed 55 breast cancer specimens, 26 adjacent ductal carcinomas in situ (DCIS) and 23 adjacent normal breast tissues for expression of glycolytic markers by immunohistochemistry. We found expression of pAkt in 49%, GLUT1 in 25%, M2PK in 68% and TKTL1 in 31% of the tumours investigated. Expression of pAkt and Her2neu are positively correlated with borderline significance (P = 0.055). Expression of pAkt, GLUT1 and TKTL1 were higher in breast cancer and DCIS than in normal tissue. Surprisingly, M2PK expression was highest in normal breast tissue. We found a glycolytic phenotype in a high percentage of breast cancer samples. Inhibition of glycolysis might evolve as a future option for breast cancer therapy.
- Open Access
- 1 January 2009
- Published by Springer Nature in Diagnostic Pathology
- Vol. 4 (1) , 18
Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses
Adenoid cystic carcinomas are rare tumors with an indolent clinical course, but frequent local relapses. The identification of tumors with a higher relapse risk seems to be interesting. Hence we investigated parameters of glucose metabolism, which were found associated with poor prognosis in other malignancies.
- 1 January 2009
- Published by Springer Nature in Diagnostic Pathology
- Vol. 4 (1) , 18
Open AccessExpression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses
Adenoid cystic carcinomas are rare tumors with an indolent clinical course, but frequent local relapses. The identification of tumors with a higher relapse risk seems to be interesting. Hence we investigated parameters of glucose metabolism, which were found associated with poor prognosis in other malignancies.
- 18 July 2008
- Vol. 28, 1719-24
Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.
Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells. The impact of autocrine signalling loops on treatment with VEGF inhibitors is still unclear. Six breast cancer cell lines were tested for expression of VEGFR-1 by RT-PCR and Western blot. To assess clinical significance, 93 breast cancer lesions were evaluated for expression of VEGF and VEGFR-1 by immunohistochemistry. VEGFR-1 mRNA was found in all 6 cell lines, while protein expression was found in 5 cell lines. VEGF was expressed in 60% and VEGFR-1 in 39% of breast cancer specimens. VEGFR-1 expression was associated with VEGF expression and with node-negative tumour stage. Our data suggest that analysis of VEGF/VEGFR-1 expression might be relevant in identifying patients with different response rates upon treatment with antiangiogenic agents.
- 18 July 2008
- Vol. 28, 1719-24
Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.
Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells. The impact of autocrine signalling loops on treatment with VEGF inhibitors is still unclear. Six breast cancer cell lines were tested for expression of VEGFR-1 by RT-PCR and Western blot. To assess clinical significance, 93 breast cancer lesions were evaluated for expression of VEGF and VEGFR-1 by immunohistochemistry. VEGFR-1 mRNA was found in all 6 cell lines, while protein expression was found in 5 cell lines. VEGF was expressed in 60% and VEGFR-1 in 39% of breast cancer specimens. VEGFR-1 expression was associated with VEGF expression and with node-negative tumour stage. Our data suggest that analysis of VEGF/VEGFR-1 expression might be relevant in identifying patients with different response rates upon treatment with antiangiogenic agents.
- 1 January 2008
- Vol. 29 (3) , 285-8
Primary vaginal melanoma: a case report and literature review.
Malignant melanoma of the vagina is a rare malignancy associated with high risk of recurrence, distant metastasis and short survival time. Due to the rarity of the disease, no prospective studies or validated treatment recommendations exist. We describe the case of a 54-year-old patient with a locally advanced melanoma located on the anterior vaginal wall. At the time of diagnosis there was no evidence of nodal or distant metastasis. In view of retrospective data in the literature, we treated the patient with colpectomy in terms of a wide local excision only. A more radical approach, adjuvant radio- or chemotherapy did not seem to be justifiable since there are no data demonstrating prolonged survival.
- 1 January 2008
- Vol. 29 (3) , 285-8
Primary vaginal melanoma: a case report and literature review.
Malignant melanoma of the vagina is a rare malignancy associated with high risk of recurrence, distant metastasis and short survival time. Due to the rarity of the disease, no prospective studies or validated treatment recommendations exist. We describe the case of a 54-year-old patient with a locally advanced melanoma located on the anterior vaginal wall. At the time of diagnosis there was no evidence of nodal or distant metastasis. In view of retrospective data in the literature, we treated the patient with colpectomy in terms of a wide local excision only. A more radical approach, adjuvant radio- or chemotherapy did not seem to be justifiable since there are no data demonstrating prolonged survival.
- 1 August 2007
- Published by Spandidos Publications in Oncology Reports
- Vol. 18 (2) , 457-463
Characterization of an intramolecular protein-protein interaction in c-Ets1 and its viral homologue v-Ets.
The proto-oncoprotein c-Ets1 is a well-known transcription factor that belongs to the Ets family and plays a role in haematopoietic differentiation, angiogenesis, and carcinogenesis. Ets family members share a unique DNA binding domain, the Ets domain, and are known to control DNA binding activity and transcriptional activation by autoinhibition. In c-Ets1 the DNA binding domain as well as N-terminal and C-terminal inhibitory domains are involved in autoinhibitory regulation. It has been proposed that intramolecular interactions are part of the autoinhibitory mechanism. We applied a GST pull-down assay as well as a two-hybrid system in yeast to show an interaction between the DNA binding domain of c-Ets1 and a domain N-terminal thereof. We have mapped the interaction sites within both of the c-Ets1 domains. Comparison of the analogous intramolecular interaction in c-Ets1 and in v-Ets revealed that the interaction we detected is stronger in v-Ets than in c-Ets1. In view of previous findings from DNA binding studies, and kinetic experiments as well as structural data, our results suggest a new model as to how intramolecular interactions might participate in the regulation of DNA binding. Binding of c-Ets1 to DNA temporarily changes the intramolecular pattern of interaction in c-Ets1, leading to an increase in affinity of c-Ets1 to DNA. In full-length c-Ets1 the intramolecular interactions re-form spontaneously and the protein-DNA complex dissociates. The interaction we characterize herein might increase the DNA binding affinity temporarily in DNA-bound c-Ets1. In v-Ets in which the C-terminal domain is mutated this interaction appears to lead to strong DNA binding affinity. Therefore, changes in v-Ets might contribute to the tumorigenic process by altering intramolecular interactions.
- 1 August 2007
- Published by Spandidos Publications in Oncology Reports
- Vol. 18 (2) , 457-463
Characterization of an intramolecular protein-protein interaction in c-Ets1 and its viral homologue v-Ets.
The proto-oncoprotein c-Ets1 is a well-known transcription factor that belongs to the Ets family and plays a role in haematopoietic differentiation, angiogenesis, and carcinogenesis. Ets family members share a unique DNA binding domain, the Ets domain, and are known to control DNA binding activity and transcriptional activation by autoinhibition. In c-Ets1 the DNA binding domain as well as N-terminal and C-terminal inhibitory domains are involved in autoinhibitory regulation. It has been proposed that intramolecular interactions are part of the autoinhibitory mechanism. We applied a GST pull-down assay as well as a two-hybrid system in yeast to show an interaction between the DNA binding domain of c-Ets1 and a domain N-terminal thereof. We have mapped the interaction sites within both of the c-Ets1 domains. Comparison of the analogous intramolecular interaction in c-Ets1 and in v-Ets revealed that the interaction we detected is stronger in v-Ets than in c-Ets1. In view of previous findings from DNA binding studies, and kinetic experiments as well as structural data, our results suggest a new model as to how intramolecular interactions might participate in the regulation of DNA binding. Binding of c-Ets1 to DNA temporarily changes the intramolecular pattern of interaction in c-Ets1, leading to an increase in affinity of c-Ets1 to DNA. In full-length c-Ets1 the intramolecular interactions re-form spontaneously and the protein-DNA complex dissociates. The interaction we characterize herein might increase the DNA binding affinity temporarily in DNA-bound c-Ets1. In v-Ets in which the C-terminal domain is mutated this interaction appears to lead to strong DNA binding affinity. Therefore, changes in v-Ets might contribute to the tumorigenic process by altering intramolecular interactions.
- 1 March 2007
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 30 (3) , 565-572
A novel breast cancer cell line initially established from pleural effusion: evolution towards a more aggressive phenotype.
Many human breast cancer cell lines have been in culture for several years, serving as model systems for studying aspects of breast cancer biology. Molecular alterations might occur in these cells during cultivation, and it remains unknown to which extent findings in these cell lines can be related to human disease. Hereby, we describe the establishment of a breast cancer cell line, MW1, from malignant pleural effusion. We compare expression patterns of several molecular markers in breast biopsy tissue, in cultivated tumor cells derived from pleural effusion reflecting the metastatic state, and in late passages of a lineage derived from the pleural culture. Our data show that expression of estrogen and progesterone receptors was lost in the cultivated tumor cells derived from pleural effusion as shown by immunohistochemical staining. Cytokeratin expression patterns remained luminal. During cultivation, the growth rate of MW1 cells increased dramatically and the morphology underwent alterations. As shown by Western blotting, E-cadherin expression remained unchanged whereas P-cadherin expression had increased after 4 years of cultivation of the cell line. Integrin beta4 expression was low in early passages of the pleural effusion whereas the cell line exhibited high expression levels of beta4. HGF receptor (c-Met), EGF receptor, VEGF and VEGF receptor-2 (KDR) expression was detectable by semiquantitative RT-PCR and remained unchanged during cultivation. In contrast, VEGF receptor-1 (flt-1) expression showed lower expression after 4 years of cultivation. The cell line migrated towards HGF, but not towards VEGF. This study provides exemplary insight into the molecular metamorphosis tumor cells undergo in vivo or in vitro on their way from the primary tumor via an equivalent of the metastatic state and during the development of a clonal cell line.
- 1 March 2007
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 30 (3) , 565-572
A novel breast cancer cell line initially established from pleural effusion: evolution towards a more aggressive phenotype.
Many human breast cancer cell lines have been in culture for several years, serving as model systems for studying aspects of breast cancer biology. Molecular alterations might occur in these cells during cultivation, and it remains unknown to which extent findings in these cell lines can be related to human disease. Hereby, we describe the establishment of a breast cancer cell line, MW1, from malignant pleural effusion. We compare expression patterns of several molecular markers in breast biopsy tissue, in cultivated tumor cells derived from pleural effusion reflecting the metastatic state, and in late passages of a lineage derived from the pleural culture. Our data show that expression of estrogen and progesterone receptors was lost in the cultivated tumor cells derived from pleural effusion as shown by immunohistochemical staining. Cytokeratin expression patterns remained luminal. During cultivation, the growth rate of MW1 cells increased dramatically and the morphology underwent alterations. As shown by Western blotting, E-cadherin expression remained unchanged whereas P-cadherin expression had increased after 4 years of cultivation of the cell line. Integrin beta4 expression was low in early passages of the pleural effusion whereas the cell line exhibited high expression levels of beta4. HGF receptor (c-Met), EGF receptor, VEGF and VEGF receptor-2 (KDR) expression was detectable by semiquantitative RT-PCR and remained unchanged during cultivation. In contrast, VEGF receptor-1 (flt-1) expression showed lower expression after 4 years of cultivation. The cell line migrated towards HGF, but not towards VEGF. This study provides exemplary insight into the molecular metamorphosis tumor cells undergo in vivo or in vitro on their way from the primary tumor via an equivalent of the metastatic state and during the development of a clonal cell line.